RxDoctor Payments Data

Patrik Zetterlund, MD

Interventional Cardiology · Salinas, CANPI 1942208848

Payments from drug & device makers

$11,631in general payments, 2019–2025

Across 449 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$3K
  • Novartis$705
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$498
  • E.r. Squibb & Sons, L.L.C.$467
  • Amgen$389
  • plus $4K from 41 others

What the payments were for

  • Travel & lodging$3,29628%
  • Food & beverage$8,19470%
  • Education$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,631 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$315,963
Medicare patients
2,536
Services billed
4,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$120,776
Repatha SureclickEvolocumab95$76,594
XareltoRivaroxaban31$35,235
EntrestoSacubitril/Valsartan25$33,172
BrilintaTicagrelor41$26,246
Ezetimibe121$4,988
Rosuvastatin Calcium238$4,314
Amiodarone Hcl34$3,734
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide108$3,527
Clonidine24$3,250
Pitavastatin Calcium14$3,238
Metoprolol Succinate210$2,910
ClopidogrelClopidogrel Bisulfate213$2,866
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide39$2,385
Valsartan85$2,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$120,776138 claims
Johnson & JohnsonXarelto$352$35,23531 claims
NovartisEntresto$705$33,17225 claims
AstraZenecaBrilinta$291$26,24641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →